Efficacy and Safety of Sequential Hormone Therapy and Tetuzumab Therapy in Patients With Moderate to Severe TAO in the Active Stage After Glucocorticoid Treatment.
Launched by SHANGHAI CHANGZHENG HOSPITAL ยท
Trial Information
Current as of November 12, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new treatment called Tetuzumab (IBI311) for people with moderate to severe thyroid-associated ophthalmopathy (TAO), an eye condition related to thyroid disease. TAO can cause symptoms like eye swelling, discomfort, and in serious cases, vision problems or even blindness. This study focuses on patients who still have active symptoms after receiving standard steroid treatment (glucocorticoids). The goal is to see if Tetuzumab can safely improve eye symptoms by targeting specific cells that contribute to the disease, and to better understand how well this treatment works in this group of patients.
People eligible for this trial are adults with moderate to severe active TAO who have already undergone steroid treatment but still have symptoms. Participants will receive Tetuzumab and be closely monitored to check for improvements and any side effects. This study is currently recruiting adults of all genders who meet the criteria. If you or a loved one has ongoing eye problems linked to thyroid disease despite steroid treatment, this trial may offer a new option to explore with your doctor.
Gender
ALL
Eligibility criteria
About Shanghai Changzheng Hospital
Shanghai Changzheng Hospital, affiliated with the Second Military Medical University, is a leading medical institution in China known for its comprehensive clinical services and advanced research capabilities. With a commitment to improving patient outcomes and advancing medical knowledge, the hospital actively engages in clinical trials across various therapeutic areas. Its multidisciplinary team of healthcare professionals collaborates with researchers and industry partners to facilitate innovative studies, ensuring adherence to the highest ethical and regulatory standards. By leveraging its state-of-the-art facilities and expertise, Shanghai Changzheng Hospital aims to contribute significantly to the development of new treatments and therapies that enhance patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported